Business Wire

1. Dow AgroSciences, BioDuro To Collaborate On Crop Protection Discovery Research
   2/7/2012
   Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, and BioDuro, a PPD Company, announced recently a three-year, multi-program discovery research agreement to generate novel molecules for synthesizing and testing fungicides, insecticides, and herbicides across a variety of crops.
2. China Emerging As An Innovation Hub For Formulation And Delivery
   2/7/2012
   A clutch of promising Chinese companies in the formulation and delivery (F/D) market underlines the emergence of the Asian giant as a center for biopharma innovation and entrepreneurship, even as Western pharmaceutical companies continue to enjoy technological and business advantages, according to a Lux Research report titled, "The Expanding Formulation and Delivery Market in China."
3. Arcadia Receives $4.5M Grant From USAID To Develop Salt-Tolerant Rice And Gather Greenhouse Gas Emissions Data From Nitrogen Efficient Crops
   1/31/2012
   Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, recentlyy announced that it has been awarded a 5-year, $4.5M grant from the U.S. Agency for International Development (USAID) to develop salt-tolerant rice and measure greenhouse gas emissions from conventional rice fields in Bangladesh and Nitrogen Use Efficient (NUE) crops in Indonesia.
4. BioSante Pharmaceuticals Provides Corporate Update
   1/31/2012
   BioSante Pharmaceuticals, Inc. recently announced a corporate update.
5. Bionest And PMC Address Optimization Of Personalized Medicine Strategies
   1/31/2012
   Bionest Partners, a premier strategy and management consulting firm for life science industries, and a recognized leader in personalized medicine strategy consulting, announces the publication of an article in a supplement to the Dec. 23, 2011 issue of Science.
6. BioLineRx Signs Exclusive License Agreement For BL-8020, An Oral Treatment For Hepatitis C
   1/24/2012
   BioLineRx, a biopharmaceutical development company, announced recently it has signed a worldwide, exclusive license agreement with Genoscience, a French company focused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C. BL-8020 has been developed for anti-viral therapy by Professor Philippe Halfon, Co-Founder and President of Genoscience.
7. Genzyme Announces FDA Approval Of Framingham Manufacturing Plant
   1/24/2012
   Genzyme, a Sanofi company, announced recently that the Food and Drug Administration (FDA) has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme (agalsidase beta). This follows the previously announced approval by the European Medicines Agency (EMA) last week.
8. Selventa Granted Patent For Discovery Of Biomarker Profiles
   1/23/2012
   Selventa, a biomarker discovery company that enables personalized healthcare through stratification of patients based on disease-driving mechanisms, recently announced that the U.S. Patent & Trademark Office has issued the Company U.S. Patent No 8,802,109, titled "Computer-aided Discovery of Biomarker Profiles in Complex Biological Systems."
9. Precision BioSciences Announces That The US Patent Office Rejects All Claims To Cellectis Patent
   1/23/2012
   Precision BioSciences, Inc., a leader in the field of genome engineering, recently announced that the United States Patent and Trademark Office (PTO) has issued a first, non-final Office Action in the reexamination proceedings for U.S. Pat. No. 7,897,372 ("the ‘372 patent") that is owned by Cellectis SA. Importantly, this Office Action rejected every claim of the ‘372 patent as being anticipated by or obvious in view of prior art.
10. FDA Updates TYSABRI (Natalizumab) Label To Include Anti-JC Virus Antibody Status As A PML Risk Factor
    1/20/2012
    Recently Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS).

First 1 2 3 4 5 6 7 8 9 10 10 (Last)